Ameriprise
KYMR icon

Ameriprise’s Kymera Therapeutics KYMR Stock Holding History

Ameriprise’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
11,650
+8,292
+247% +$712K ﹤0.01% 3277
2026
Q1 		$280K Sell
3,358
-68
-2% -$5.38K ﹤0.01% 3779
2025
Q4 		$267K Sell
3,426
-20,632
-86% -$1.39M ﹤0.01% 3842
2025
Q3 		$1.36M Buy
24,058
+4,525
+23% +$204K ﹤0.01% 3205
2025
Q2 		$852K Buy
19,533
+4,159
+27% +$143K ﹤0.01% 3333
2025
Q1 		$421K Buy
15,374
+6,830
+80% +$249K ﹤0.01% 3557
2024
Q4 		$344K Buy
+8,544
New +$386K ﹤0.01% 3668
2023
Q2 		– Sell
-7,470
Closed -$221K – 3960
2023
Q1 		$221K Buy
+7,470
New +$241K ﹤0.01% 3700

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Ameriprise's KYMR Position: Q2 2026 in Review

Ameriprise increased its Kymera Therapeutics (KYMR) stake by 247% in Q2 2026, buying an estimated $712K and bringing the position to 11,650 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3277.

Ameriprise first reported a position in KYMR in Q1 2023 and has held it in 8 quarters since. The position peaked at $1.36M in Q3 2025. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Ameriprise held 11,650 shares of Kymera Therapeutics worth $1.34M as of Q2 2026.
  • Ameriprise bought 8,292 Kymera Therapeutics shares in Q2 2026, an estimated $712K.
  • Kymera Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3277 holding.
  • Ameriprise first reported a position in Kymera Therapeutics in Q1 2023 and has held it in 8 quarters since.
  • Ameriprise's Kymera Therapeutics position peaked at $1.36M in Q3 2025.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.